Daraxonrasib Improves Survival Outcomes in Previously Treated Metastatic Pancreatic Cancer
Clinical Summary:
-
Design/Population: The phase 3 RASolute 302 trial randomized patients with second-line metastatic pancreatic ductal adenocarcinoma to receive daraxonrasib or investigator’s choice of standard cytotoxic chemotherapy.
- Key Outcomes: Daraxonrasib significantly improved survival versus chemotherapy and was generally well tolerated.
- Clinical Relevance: Daraxonrasib may establish a new standard of care for second-line metastatic pancreatic ductal adenocarcinoma, offering a targeted oral option with improved efficacy and a manageable safety profile across patients with and without identified RAS mutations.
Brian Wolpin, MD, MPH, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from the phase 3 RASolute 302 trial which demonstrated that daraxonrasib, a first-in-class RAS(ON) multi-selective inhibitor, significantly improved both overall survival (OS) and progression-free survival (PFS) compared with standard chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma.
Benefits were observed in patients with RAS G12 mutations as well as in the overall study population, while maintaining a manageable safety profile with fewer severe adverse events and treatment discontinuations.
Dr Wolpin presented these results in a plenary session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Source:
Wolpin BM, Wainberg ZA, Hendifar A, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. LBA5.
